Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) FCF Margin (2022 - 2025)

Historic FCF Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1035.75%.

  • Taysha Gene Therapies' FCF Margin rose 9254900.0% to 1035.75% in Q2 2025 from the same period last year, while for Sep 2025 it was 1349.64%, marking a year-over-year decrease of 5485600.0%. This contributed to the annual value of 979.23% for FY2024, which is 4816100.0% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported FCF Margin of 1035.75% as of Q2 2025, which was up 9254900.0% from 957.56% recorded in Q1 2025.
  • In the past 5 years, Taysha Gene Therapies' FCF Margin registered a high of 7346.13% during Q1 2022, and its lowest value of 1961.24% during Q2 2024.
  • For the 4-year period, Taysha Gene Therapies' FCF Margin averaged around 431.01%, with its median value being 683.05% (2023).
  • As far as peak fluctuations go, Taysha Gene Therapies' FCF Margin crashed by -78579200bps in 2023, and later soared by 9254900bps in 2025.
  • Taysha Gene Therapies' FCF Margin (Quarter) stood at 950.42% in 2022, then surged by 53bps to 447.67% in 2023, then plummeted by -102bps to 905.34% in 2024, then dropped by -14bps to 1035.75% in 2025.
  • Its FCF Margin stands at 1035.75% for Q2 2025, versus 957.56% for Q1 2025 and 905.34% for Q4 2024.